NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, announced that independent analyst Robert LeBoyer of Noble Capital Markets has initiated research coverage with an “Outperform” rating and a $6.00 price target. The report reviews the company’s lead programs, including its broad-spectrum antiviral candidate NV-387, along with longer-term development initiatives. NanoViricides noted that while it provided publicly available information and answered technical questions, the analyst independently developed all estimates, financial models and projections.
Separately, the company announced that President and Executive Chairman Anil R. Diwan participated in a “Fireside Chat” published by StockInvestor Daily’s IPO-Edge program, where he discussed NanoViricides’ antiviral technology platform, the potential of NV-387 against multiple viral diseases and variants, the company’s regulatory progress, including FDA Orphan Drug Designation and its Rare Pediatric Disease Designation filing for measles, as well as the resurgence of infectious diseases such as measles, mpox and Ebola.
The initiation of coverage by Noble Capital Markets underscores growing investor interest in NanoViricides’ novel nanoviricide class of drug candidates. The company’s lead drug candidate, NV-387, is a broad-spectrum antiviral designed to treat RSV, COVID-19, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox and Measles. NV-387 is currently being advanced into Phase II human clinical trials.
NanoViricides’ platform technology is based on TheraCour nanomedicine technology, licensed from TheraCour Pharma, Inc. The company holds a worldwide exclusive perpetual license for several drugs targeting specific viral diseases, including HIV/AIDS, Hepatitis B and C, Rabies, Herpes, Influenza, Dengue, Ebola, and certain Coronaviruses. The company also has drug candidates NV-CoV-2 and NV-CoV-2-R for COVID-19, with the latter encapsulating remdesivir, an FDA-approved antiviral.
The $6.00 price target from Noble Capital Markets suggests significant upside from current trading levels, reflecting confidence in the company’s pipeline and regulatory milestones. The FDA Orphan Drug Designation and Rare Pediatric Disease Designation filing for measles could provide incentives for development, including potential priority review vouchers. The resurgence of infectious diseases like measles, mpox, and Ebola highlights the need for broad-spectrum antivirals, positioning NanoViricides’ technology as a potential solution.
For investors, the analyst coverage provides an independent assessment of the company’s prospects. However, as with any drug development efforts, there can be no assurance that any of the company’s pharmaceutical candidates will show sufficient effectiveness and safety for human clinical development. The path to drug development is lengthy and requires substantial capital.
NanoViricides’ business model is based on licensing technology from TheraCour Pharma for specific application verticals. The company has developed both of its own drug candidates independently, including NV-CoV-2 and NV-CoV-2-R. The company is also developing drugs against oral and genital Herpes, viral diseases of the eye, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.
The latest news and updates relating to NNVC are available in the company’s newsroom at https://ibn.fm/NNVC. For the full press release, visit https://ibn.fm/7XBbY.
